State of the Art-and Science-of Psychiatry: Highlights of the APA 2014 Annual Meeting
April 22nd 2014There’s a lot going on at the American Psychiatric Association Annual Meeting in the Big Apple this year . . . so much, in fact, that we’ve invited the Chair of Scientific Program Committee, Dr Philip R. Muskin, to provide you with a road map. More in this podcast.
A Eulogy for Psychiatry's Abraham: A Model of Ethics, Forensics, Advocacy, and Humanitarianism
June 7th 2013At the recent annual APA meeting, Dr Abraham Halpern was posthumously honored for the second annual Humanitarian Award by the American Association for Social Psychiatry. He was honored for his contributions to ethics, forensics, and advocacy of social issues.
Successful Aging: Strategies to Help Maintain and Nurture a Healthy Brain
May 20th 2013Our brains can be trained to function better as we age, and it doesn't take the Fountain of Youth to get there. In this podcast, geriatric psychiatrist Helen Lavretsky prescribes strategies to challenge our brains. She notes: "The more we challenge our brain, the more new nerve pathways and circuits we form."
The Paradox of Choice: When More Medications Mean Less Treatment
May 16th 2013Two problems persist in the treatment of severe mental illness that constitute a barrier to effective patient-centered care: excessive reliance on a limited number of antipsychotic medications at the expense of other effective treatments, and the underutilization of other evidence-based treatment options.
Behavioral Dysinhibition: Impulsivity and Borderline Personality Disorder
May 31st 2012Neural underpinnings and symptom presentation in borderline personality disorder might explain similarities and differences in this symptom domain across the spectrum of personality disorders as well as in other disorders associated with impulsive symptoms.
Update on Opioid Dependence and Its Treatment
May 11th 2012While regulatory controls on methadone clinics for opioid dependence resulted in treatment being physically and functionally isolated from conventional medical care, the delivery of an office-based treatment of buprenorphine and the buprenorphine/naloxone combination product over the last decade has facilitated the return of treatment to “mainstream medicine both for psychiatry and primary care."